[{"id":"1c2892ea-1261-4dae-afe1-c46131b3f056","acronym":"","url":"https://clinicaltrials.gov/study/NCT07039760","created_at":"2025-06-28T13:40:51.525Z","updated_at":"2025-06-28T13:40:51.525Z","phase":"Phase 1","brief_title":"Asciminib With or Without Sildenafil for Brain Tumors","source_id_and_acronym":"NCT07039760","lead_sponsor":"Washington University School of Medicine","biomarkers":" CRKL • ABL2","pipe":"","alterations":" ","tags":["CRKL • ABL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Scemblix (asciminib) • sildenafil"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 12/01/2025","start_date":" 12/01/2025","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-06-26"},{"id":"463898f9-d0f2-4eeb-ad5a-ad7d4f465a1f","acronym":"ASC4MORE","url":"https://clinicaltrials.gov/study/NCT03578367","created_at":"2021-01-18T17:36:31.183Z","updated_at":"2025-02-25T14:39:57.704Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)","source_id_and_acronym":"NCT03578367 - ASC4MORE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • nilotinib • Scemblix (asciminib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 11/22/2018","start_date":" 11/22/2018","primary_txt":" Primary completion: 11/08/2021","primary_completion_date":" 11/08/2021","study_txt":" Completion: 02/27/2025","study_completion_date":" 02/27/2025","last_update_posted":"2025-02-14"},{"id":"4031ba62-5860-47d7-91f9-d7064a25a760","acronym":"","url":"https://clinicaltrials.gov/study/NCT04795427","created_at":"2021-03-12T15:52:52.806Z","updated_at":"2025-02-25T15:12:00.303Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors","source_id_and_acronym":"NCT04795427","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Scemblix (asciminib)"],"overall_status":"Completed","enrollment":" Enrollment 84","initiation":"Initiation: 12/06/2021","start_date":" 12/06/2021","primary_txt":" Primary completion: 05/29/2023","primary_completion_date":" 05/29/2023","study_txt":" Completion: 11/18/2024","study_completion_date":" 11/18/2024","last_update_posted":"2025-02-13"},{"id":"03bbf3c8-c3f3-4829-8090-3434c8fc4bb8","acronym":"ASC4START","url":"https://clinicaltrials.gov/study/NCT05456191","created_at":"2022-07-13T12:56:30.124Z","updated_at":"2025-02-25T16:46:11.226Z","phase":"Phase 3","brief_title":"A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)","source_id_and_acronym":"NCT05456191 - ASC4START","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1","pipe":"","alterations":" ","tags":["ABL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib • Scemblix (asciminib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 574","initiation":"Initiation: 11/21/2022","start_date":" 11/21/2022","primary_txt":" Primary completion: 03/17/2025","primary_completion_date":" 03/17/2025","study_txt":" Completion: 07/07/2031","study_completion_date":" 07/07/2031","last_update_posted":"2025-02-06"},{"id":"fdf62ac7-f79d-46b1-9a07-c4ce7608d067","acronym":"Ascembl","url":"https://clinicaltrials.gov/study/NCT03106779","created_at":"2021-01-17T17:34:34.885Z","updated_at":"2025-02-25T16:36:53.037Z","phase":"Phase 3","brief_title":"Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs","source_id_and_acronym":"NCT03106779 - Ascembl","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 mutation","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib • Scemblix (asciminib)"],"overall_status":"Completed","enrollment":" Enrollment 233","initiation":"Initiation: 10/26/2017","start_date":" 10/26/2017","primary_txt":" Primary completion: 05/25/2020","primary_completion_date":" 05/25/2020","study_txt":" Completion: 12/04/2024","study_completion_date":" 12/04/2024","last_update_posted":"2025-02-06"},{"id":"91bc7864-fd10-46ec-b629-e98e5ba03f9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06773936","created_at":"2025-02-25T15:46:10.278Z","updated_at":"2025-02-25T15:46:10.278Z","phase":"Phase 2","brief_title":"Adding Asciminib to Usual Treatment for Adults with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT06773936","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Blincyto (blinatumomab) • prednisone • Scemblix (asciminib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 03/31/2025","start_date":" 03/31/2025","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 05/01/2033","study_completion_date":" 05/01/2033","last_update_posted":"2025-01-14"},{"id":"e17fb339-f241-4fee-96fe-598ffffcf271","acronym":"ASC4REAL","url":"https://clinicaltrials.gov/study/NCT06684964","created_at":"2025-02-26T07:06:31.325Z","updated_at":"2025-02-26T07:06:31.325Z","phase":"","brief_title":"RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL)","source_id_and_acronym":"NCT06684964 - ASC4REAL","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Scemblix (asciminib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/30/2025","start_date":" 01/30/2025","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2026","study_completion_date":" 07/30/2026","last_update_posted":"2025-01-10"},{"id":"d9427140-13fb-4cb7-b7fe-49c1e6486504","acronym":"","url":"https://clinicaltrials.gov/study/NCT03595917","created_at":"2022-04-24T08:59:32.242Z","updated_at":"2025-02-25T15:43:07.761Z","phase":"Phase 1","brief_title":"ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML","source_id_and_acronym":"NCT03595917","lead_sponsor":"Marlise Luskin, MD","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Blincyto (blinatumomab) • prednisone • Scemblix (asciminib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 07/24/2018","start_date":" 07/24/2018","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-12-27"},{"id":"67208ab2-da0d-429c-a27e-8240b35e734d","acronym":"ASC4TARGET","url":"https://clinicaltrials.gov/study/NCT06514534","created_at":"2025-02-26T09:29:56.710Z","updated_at":"2025-02-26T09:29:56.710Z","phase":"Phase 2","brief_title":"Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.","source_id_and_acronym":"NCT06514534 - ASC4TARGET","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib) • Scemblix (asciminib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/02/2024","start_date":" 12/02/2024","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-07-23"},{"id":"aadf45af-534e-4166-a814-b17b7ba47bd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06516029","created_at":"2025-02-26T09:29:57.175Z","updated_at":"2025-02-26T09:29:57.175Z","phase":"","brief_title":"Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Asciminib","source_id_and_acronym":"NCT06516029","lead_sponsor":"Novartis","biomarkers":" ABL1","pipe":"","alterations":" ","tags":["ABL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Scemblix (asciminib)"],"overall_status":"Completed","enrollment":" Enrollment 111","initiation":"Initiation: 04/21/2023","start_date":" 04/21/2023","primary_txt":" Primary completion: 10/02/2023","primary_completion_date":" 10/02/2023","study_txt":" Completion: 10/02/2023","study_completion_date":" 10/02/2023","last_update_posted":"2024-07-23"},{"id":"40b74cbe-0048-46ef-9bea-782d3936a358","acronym":"ASC4KIDS","url":"https://clinicaltrials.gov/study/NCT04925479","created_at":"2021-06-14T18:52:41.613Z","updated_at":"2024-07-02T16:34:36.877Z","phase":"Phase 1/2","brief_title":"Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia","source_id_and_acronym":"NCT04925479 - ASC4KIDS","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Scemblix (asciminib)"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 12/27/2021","start_date":" 12/27/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 11/01/2031","study_completion_date":" 11/01/2031","last_update_posted":"2024-06-10"},{"id":"cccf3900-a510-424c-9edc-f325d48c0848","acronym":"ASC2ESCALATE","url":"https://clinicaltrials.gov/study/NCT05384587","created_at":"2022-05-20T17:58:29.879Z","updated_at":"2024-07-02T16:34:37.099Z","phase":"Phase 2","brief_title":"Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia","source_id_and_acronym":"NCT05384587 - ASC2ESCALATE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" BCR","pipe":" | ","alterations":" BCR-ABL1 mutation","tags":["BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Scemblix (asciminib)"],"overall_status":"Recruiting","enrollment":" Enrollment 182","initiation":"Initiation: 11/11/2022","start_date":" 11/11/2022","primary_txt":" Primary completion: 02/27/2026","primary_completion_date":" 02/27/2026","study_txt":" Completion: 02/26/2027","study_completion_date":" 02/26/2027","last_update_posted":"2024-06-07"},{"id":"bf879c20-915a-45bc-aa7f-bfcae5d8514b","acronym":"ASC4OPT","url":"https://clinicaltrials.gov/study/NCT04948333","created_at":"2021-07-01T14:54:54.307Z","updated_at":"2024-07-02T16:35:05.406Z","phase":"Phase 3","brief_title":"Asciminib Treatment Optimization in ≥ 3rd Line CML-CP.","source_id_and_acronym":"NCT04948333 - ASC4OPT","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Scemblix (asciminib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 199","initiation":"Initiation: 10/13/2021","start_date":" 10/13/2021","primary_txt":" Primary completion: 06/28/2024","primary_completion_date":" 06/28/2024","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-05-07"},{"id":"0e780db3-37b0-4fba-8b2c-04f23ba71bda","acronym":"ASC4FIRST","url":"https://clinicaltrials.gov/study/NCT04971226","created_at":"2021-07-21T12:52:37.177Z","updated_at":"2024-07-02T16:35:06.088Z","phase":"Phase 3","brief_title":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","source_id_and_acronym":"NCT04971226 - ASC4FIRST","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • bosutinib • Scemblix (asciminib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 404","initiation":"Initiation: 10/06/2021","start_date":" 10/06/2021","primary_txt":" Primary completion: 11/28/2023","primary_completion_date":" 11/28/2023","study_txt":" Completion: 01/18/2028","study_completion_date":" 01/18/2028","last_update_posted":"2024-05-03"},{"id":"4d198146-63bc-4094-95ef-0d64c81f21ec","acronym":"DANTE","url":"https://clinicaltrials.gov/study/NCT03874858","created_at":"2021-01-18T19:06:17.053Z","updated_at":"2024-07-02T16:35:08.487Z","phase":"Phase 2","brief_title":"De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination","source_id_and_acronym":"NCT03874858 - DANTE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR • TFRC","pipe":"","alterations":" ","tags":["ABL1 • BCR • TFRC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib • Scemblix (asciminib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 03/22/2019","start_date":" 03/22/2019","primary_txt":" Primary completion: 07/31/2026","primary_completion_date":" 07/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-04-22"},{"id":"1cd8b8e0-c288-4356-b1d4-81c289387f1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04838041","created_at":"2021-04-08T12:52:35.090Z","updated_at":"2024-07-02T16:35:11.769Z","phase":"Phase 2","brief_title":"Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation","source_id_and_acronym":"NCT04838041","lead_sponsor":"Medical College of Wisconsin","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • Scemblix (asciminib)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 11/11/2021","start_date":" 11/11/2021","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 07/01/2029","study_completion_date":" 07/01/2029","last_update_posted":"2024-04-03"},{"id":"58a13adb-b09f-4fe4-9e51-f50226226a29","acronym":"","url":"https://clinicaltrials.gov/study/NCT05143840","created_at":"2021-12-03T17:53:27.865Z","updated_at":"2024-07-02T16:35:12.755Z","phase":"Phase 2","brief_title":"Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase","source_id_and_acronym":"NCT05143840","lead_sponsor":"Augusta University","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • Scemblix (asciminib)"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 04/22/2022","start_date":" 04/22/2022","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-03-26"},{"id":"d266febd-e7eb-45d8-8721-ec2eb98b80b6","acronym":"CABL001X2101","url":"https://clinicaltrials.gov/study/NCT02081378","created_at":"2021-01-17T17:18:50.733Z","updated_at":"2024-07-02T16:35:14.287Z","phase":"Phase 1","brief_title":"A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL","source_id_and_acronym":"NCT02081378 - CABL001X2101","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • Scemblix (asciminib)"],"overall_status":"Completed","enrollment":" Enrollment 326","initiation":"Initiation: 04/24/2014","start_date":" 04/24/2014","primary_txt":" Primary completion: 06/03/2021","primary_completion_date":" 06/03/2021","study_txt":" Completion: 03/14/2023","study_completion_date":" 03/14/2023","last_update_posted":"2024-03-18"},{"id":"fb542c14-9c22-4811-95b1-a86a99321022","acronym":"","url":"https://clinicaltrials.gov/study/NCT04216563","created_at":"2021-01-18T20:31:47.275Z","updated_at":"2024-07-02T16:35:18.171Z","phase":"Phase 2","brief_title":"ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor","source_id_and_acronym":"NCT04216563","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Scemblix (asciminib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-02-22"},{"id":"7266424a-451b-4b30-b1c3-7a306a44a7a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05413915","created_at":"2022-06-10T13:57:02.867Z","updated_at":"2025-02-25T15:54:28.951Z","phase":"Phase 3","brief_title":"Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML","source_id_and_acronym":"NCT05413915","lead_sponsor":"Sarit Assouline","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Scemblix (asciminib)"],"overall_status":"Recruiting","enrollment":" Enrollment 164","initiation":"Initiation: 06/19/2023","start_date":" 06/19/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-10-23"},{"id":"af7a09a6-b7ff-45c6-968f-d00666a858dc","acronym":"AIM4CML","url":"https://clinicaltrials.gov/study/NCT04666259","created_at":"2021-01-19T20:43:43.111Z","updated_at":"2024-07-02T16:35:37.810Z","phase":"Phase 3","brief_title":"Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation","source_id_and_acronym":"NCT04666259 - AIM4CML","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" ABL1 T315I • BCR-ABL1 mutation","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL1 T315I • BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Scemblix (asciminib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 05/25/2021","start_date":" 05/25/2021","primary_txt":" Primary completion: 06/20/2023","primary_completion_date":" 06/20/2023","study_txt":" Completion: 07/05/2024","study_completion_date":" 07/05/2024","last_update_posted":"2023-09-07"},{"id":"e3855945-52c4-4e20-b997-b9e622d7cfce","acronym":"CMLXI","url":"https://clinicaltrials.gov/study/NCT03906292","created_at":"2021-01-18T19:13:48.813Z","updated_at":"2025-02-25T15:43:28.149Z","phase":"Phase 2","brief_title":"Frontline Asciminib Combination in Chronic Phase CML","source_id_and_acronym":"NCT03906292 - CMLXI","lead_sponsor":"University of Jena","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • Scemblix (asciminib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 08/19/2019","start_date":" 08/19/2019","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2023-05-10"}]